Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Patrick Lefebvre, MA
Managing Principal
Analysis Group, Inc
Montréal, Québec, Canada
Managing Principal, Analysis Group, Inc, Montréal, Québec, Canada
Authored Items
Real-World Treatment Patterns and Healthcare Costs Among Patients with FL with Early Treatment Failure of First-Line Chemoimmunotherapy
Lori A. Leslie, MD
,
Bruno Emond, MSc
,
Marie-Hélène Lafeuille, MA
,
Maude Vermette-Laforme, BSc
,
Patrick Lefebvre, MA
,
Qing Huang, PhD, MHS
September 2022 Vol 15, No 3
in
Original Research
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy
Dominic Pilon, MA
,
Brian Caveney, MD, JD, MPH
,
Ajay S. Behl, PhD
,
Lorie A. Ellis, PhD
,
Marie-Noëlle Robitaille, MA
,
Patrick Lefebvre, MA
,
Nancy A. Dawson, MD
May 2017 Vol 10, No 3
in
Original Research
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia
Marie-Hélène Lafeuille, MA
,
Michael F. Murphy, MD, PhD
,
Christian Frois, PhD
,
Michel Cloutier, PhD
,
Mei Sheng Duh, MPH, ScD
,
Patrick Lefebvre, MA
,
Jacqueline Pesa, PhD, MPH
,
Zoe Clancy, PharmD
,
John Fastenau, RPh, MPH
,
Mike Durkin, MSc
October 2016 Vol 9, No 7
in
Original Research
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer
Lorie A. Ellis, PhD
,
Laurence Gozalo, PhD
,
Marie-Hélène Lafeuille, MA
,
Patrick Lefebvre, MA
,
Scott McKenzie, MD
,
Dominic Pilon, MA
,
Matthew Mitchell, PharmD, MBA, FAMCP
June 2015, Vol 8, No 4
in
Practice Management
Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases
Marie-Hélène Lafeuille, MA
,
Atheer A. Kaddis, PharmD
,
Jonathan Gravel, MSc
,
Amanda Grittner, MA
,
Patrick Lefebvre, MA
,
Lorie A. Ellis, PhD
,
Scott McKenzie, MD
July/August 2013 Vol 6, No 6
in
Practice Management
Last modified: September 27, 2022